AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Athira Pharma will effect a 10-for-1 reverse stock split to comply with Nasdaq's $1 minimum bid price requirement. The split will become effective on September 17, 2025, and trading will begin on September 18, 2025. The total number of authorized shares will be reduced from 900 million to 90 million, and the par value per share will remain at $0.0001. Proportional adjustments will be made to outstanding options, restricted stock units, and equity incentive plans.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet